JP2016502522A5 - - Google Patents

Download PDF

Info

Publication number
JP2016502522A5
JP2016502522A5 JP2015542135A JP2015542135A JP2016502522A5 JP 2016502522 A5 JP2016502522 A5 JP 2016502522A5 JP 2015542135 A JP2015542135 A JP 2015542135A JP 2015542135 A JP2015542135 A JP 2015542135A JP 2016502522 A5 JP2016502522 A5 JP 2016502522A5
Authority
JP
Japan
Prior art keywords
ethyl
purin
pyrrolidin
methylpyrimidin
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015542135A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016502522A (ja
JP6322200B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2013/001395 external-priority patent/WO2014075393A1/en
Publication of JP2016502522A publication Critical patent/JP2016502522A/ja
Publication of JP2016502522A5 publication Critical patent/JP2016502522A5/ja
Application granted granted Critical
Publication of JP6322200B2 publication Critical patent/JP6322200B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015542135A 2012-11-16 2013-11-15 ヒトホスファチジルイノシトール3−キナーゼデルタのプリン阻害剤 Active JP6322200B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261727392P 2012-11-16 2012-11-16
US61/727,392 2012-11-16
PCT/CN2013/001395 WO2014075393A1 (en) 2012-11-16 2013-11-15 Purine inhibitors of human phosphatidylinositol 3-kinase delta

Publications (3)

Publication Number Publication Date
JP2016502522A JP2016502522A (ja) 2016-01-28
JP2016502522A5 true JP2016502522A5 (OSRAM) 2016-12-22
JP6322200B2 JP6322200B2 (ja) 2018-05-09

Family

ID=50730542

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015542135A Active JP6322200B2 (ja) 2012-11-16 2013-11-15 ヒトホスファチジルイノシトール3−キナーゼデルタのプリン阻害剤

Country Status (11)

Country Link
US (1) US9938281B2 (OSRAM)
EP (1) EP2920172B1 (OSRAM)
JP (1) JP6322200B2 (OSRAM)
KR (1) KR20150084992A (OSRAM)
CN (1) CN104918940B (OSRAM)
AU (1) AU2013347539B2 (OSRAM)
BR (1) BR112015011147A8 (OSRAM)
CA (1) CA2891013A1 (OSRAM)
MX (1) MX2015006192A (OSRAM)
RU (1) RU2661896C2 (OSRAM)
WO (1) WO2014075393A1 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2240451T3 (da) 2008-01-04 2017-11-20 Intellikine Llc Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
DK2663309T3 (en) 2011-01-10 2017-06-19 Infinity Pharmaceuticals Inc METHODS FOR PRODUCING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
KR102229478B1 (ko) 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015178955A1 (en) * 2014-05-19 2015-11-26 Eternity Bioscience Inc. Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
WO2015188369A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
KR101710127B1 (ko) * 2014-08-29 2017-02-27 한화제약주식회사 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민
WO2017000125A1 (en) * 2015-06-29 2017-01-05 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
WO2017166104A1 (en) * 2016-03-30 2017-10-05 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
IL263680B2 (en) 2016-06-24 2025-10-01 Infinity Pharmaceuticals Inc PI3K inhibitors for use in combination with a second therapeutic agent for the treatment, management or prevention of cancer
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
CN108892635A (zh) * 2018-09-07 2018-11-27 江苏工程职业技术学院 一种西沙必利关键中间体的制备方法
AU2020207051B2 (en) * 2019-01-08 2025-07-24 Corxel Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
LT4069691T (lt) 2019-12-06 2024-12-10 Vertex Pharmaceuticals Incorporated Pakeistieji tetrahidrofuranai kaip natrio kanalų moduliatoriai
DK4347031T3 (da) 2021-06-04 2025-12-01 Vertex Pharma N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler
CN120092008A (zh) * 2022-10-20 2025-06-03 上海瑛派药业有限公司 取代的杂芳基双环化合物作为usp1抑制剂及其应用
WO2024127350A1 (en) 2022-12-16 2024-06-20 Astrazeneca Ab 2,6,9-trisubstituted purines

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5117830A (en) 1990-11-08 1992-06-02 Whitby Research, Inc. Method of determining viability of tissue
US5877179A (en) * 1992-09-29 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
RU2112765C1 (ru) * 1993-02-09 1998-06-10 Дзе Велкам Фаундейшн Лимитед ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ПРОЯВЛЯЮЩАЯ АКТИВНОСТЬ ПРОТИВ ВИРУСНОЙ ИНФЕКЦИИ И β D-АРАБИНОФУРАНОЗИЛ-2-АМИНО-6-МЕТОКСИ-9Н-ПУРИНЫ
US5670501A (en) 1994-09-01 1997-09-23 Discovery Therapeutics, Inc. N-substituted 9-alkyladenines
SK11822001A3 (sk) * 1999-03-26 2002-09-10 Astrazeneca Ab Modulátory chemokínovej aktivity, spôsoby ich prípravy, farmaceutické kompozície s ich obsahom a ich použitie v terapii
US7625909B2 (en) 2003-05-23 2009-12-01 Novartis Vaccines And Diagnostics, Inc. Substituted quinazolinone compounds
JP2007535560A (ja) * 2004-04-28 2007-12-06 シーブイ・セラピューティクス・インコーポレイテッド A1アデノシンレセプターアンタゴニスト
HRP20161751T1 (hr) 2004-05-13 2017-04-07 Icos Corporation Kinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta
JP4820290B2 (ja) 2004-05-13 2011-11-24 第一三共株式会社 置換ピロリジン誘導体
EP1863815A1 (en) 2005-03-11 2007-12-12 Aderis Pharmaceuticals, Inc. Substituted 9-alkyladenines and the use thereof
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
US8680108B2 (en) * 2009-12-18 2014-03-25 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
DE102010011431A1 (de) * 2009-12-23 2011-06-30 WABCO GmbH, 30453 Ventileinrichtung für eine Luftfederungsanlage
CA2789189A1 (en) 2010-03-10 2011-09-15 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
JP2013522267A (ja) * 2010-03-17 2013-06-13 エフ.ホフマン−ラ ロシュ アーゲー イミダゾピリジン化合物、組成物、および使用法
EP2588473A1 (en) * 2010-06-30 2013-05-08 Amgen Inc. Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
WO2012037226A1 (en) * 2010-09-14 2012-03-22 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
EP2632898A4 (en) * 2010-10-29 2014-04-02 Biogen Idec Inc HETEROCYCLIC TYROSINE KINASE HEMMER
EP2518070A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
CN102838600A (zh) 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 苯基喹唑啉类PI3Kδ抑制剂

Similar Documents

Publication Publication Date Title
JP2016502522A5 (OSRAM)
RU2015122894A (ru) Пуриновые ингибиторы фосфатидилинозитол-3-киназы дельта человека
JP2015537010A5 (OSRAM)
RU2015122895A (ru) Пуриновые ингибиторы человеческой фосфатидилинозит 3-киназы дельта
CN118955473A (zh) 通过泛素蛋白酶体途径降解btk的双官能化合物
ES2548532T3 (es) Compuestos de pirrolopirimidina como inhibidores de CDK4/6
AU2014358792C1 (en) Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
JP2024009957A (ja) アロステリックshp2阻害剤としての2,5-二置換3-メチルピラジンおよび2,5,6-三置換3-メチルピラジン
KR101735868B1 (ko) 복소고리 화합물
JP2015522002A5 (OSRAM)
HRP20210177T1 (hr) Supstituirani spojevi pirazolo[1,5-a]piridina kao inhibitori ret kinaze
JP2019533670A (ja) Retキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピリジン化合物
TW202132297A (zh) 經取代吡啶及使用方法
JP2015527399A5 (OSRAM)
CN120641428A (zh) 用于治疗自身免疫性疾病的咪唑大环
US20240109917A1 (en) Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors
JP2017527628A5 (OSRAM)
US20250304577A1 (en) Tyk2 inhibitors
JPWO2023027518A5 (OSRAM)
WO2023247593A1 (en) Pyrrolopyridine carboxamides and their uses as pdgfr inhibitors
RU2023122794A (ru) Ингибиторы циклинзависимой киназы 7
RU2022124945A (ru) Ингибиторы циклинзависимой киназы 7
JPWO2020072504A5 (OSRAM)